Customer Service Retention/Sales Representative
About the job
- Strong communication and active listening skills.
- Confidence in sales and service scenarios.
- Ability to work independently and make sound decisions.
- High energy and a professional demeanor.
- Reliable with a strong history of attendance.
- Proficiency in basic math and data entry.
- Comfort working in a fast-paced, team-oriented environment.
- Flexibility to work a variety of shifts.
- Must be at least 18 years of age.
- High school diploma or equivalent.
- High-speed internet with a hard-wired Ethernet connection.
- A private space to work within the home.
- Ability to work full time, 40 hours per week.
- Promote and sell products and services.
- Identify customer needs and recommend the best solutions.
- Handle service and account changes accurately and professionally.
- Complete save and service orders and negotiate when needed.
- Resolve billing inquiries and adjustments.
- Deliver an outstanding customer experience.
About the company
Ibex Biosciences focuses on discovering, validating, and producing biotechnology solutions for health and ecological challenges. Its product portfolio includes therapeutic antibodies, gene therapy, and stem cell programs, as well as diagnostic antibodies for Immunohistochemistry (IHC) to improve biopsy accuracy. The company advances its products by conducting exploratory R&D on projects that may not yet be validated in public research, then develops and commercializes these technologies through licensing, partnerships, and direct sales to healthcare and research institutions. A key differentiator is Ibex’s diversified, internally driven pipeline and its mix of therapeutics and diagnostics, alongside active engagement in grant funding and patenting. The company’s goal is to bring proprietary biotech innovations to market to enhance patient outcomes and health-related research, addressing significant cancer-related and other health challenges.
Company Size
1-10
Company Stage
Early VC
Total Funding
$4.2M
Headquarters
North Bethesda, Maryland
Founded
2015
Get referred to IBEX
See people who can refer or advise you
Simplify's Take
What believers are saying
- Ibex keeps an open 506(c) offering, signaling active capital formation in 2026.
- The 2022 CD147 patent supports oncology and inflammation licensing conversations.
- Anti-MIF VHH development continues, with animal-model testing already disclosed.
What critics are saying
- Ibex has no disclosed commercial products, leaving revenue dependent on financing.
- The open Regulation D offering implies dilution risk and financing pressure through 2026.
- Without clinical validation, the company risks becoming a perpetual patent shop.
What makes IBEX unique
- North Bethesda-based Ibex Biosciences focuses on antibody, gene-therapy, and stem-cell programs.
- Its 2026 pipeline spans CD147 antibodies, anti-MIF VHHs, and PCBP1 stem-cell methods.
- Ibex still controls early patentable assets, including 2022 CD147 publication.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
Company News
IBEX has successfully completed a £2 million funding round to advance its mission of using X-ray technology to diagnose osteoporosis early. The company aims to shift from reactive to proactive treatment of this silent disease. With partnerships established with X-ray and mammography OEMs in 2024, IBEX plans to deploy its technology in clinical settings by 2025, demonstrating cost savings for the NHS.
Israeli light control nanotech and smart glass company Gauzy has announced that it has acquired French company Vision Systems, which develops ADAS (Advanced Driver Assistance System) and shading solutions for the aeronautic, land transport, and marine industries.